explore -WSS

explore

author：entertainment 2025-09-30 18:59:44 - browse：62425

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

leisure time

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Wegovy leads to weight loss. Can it treat depression, too?

The problems with dementia villages

ADCs take center stage as promising cancer treatments

Why you shouldn’t ask, “What country has the best health care?”

STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

explore

knowledge

Activists slam private health insurers over coverage restrictions

Roche drug slashes death risk in early

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Summit: How researchers deal with rejection

Bright Health sells Medicare Advantage business to Molina

New clues to why women have higher risk of autoimmune disorders

In age of alternative facts, a scholarly course on calling out crap

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Guidelines to prevent youth baseball injuries need more muscle

White House pharmacy plagued with problems, investigation finds

explore

How AI can help patients find reliable information about doctors

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Smaller biotechs seek to piggyback on weight loss drug boom

Why Medicare shouldn’t cover every FDA

Wegovy leads to weight loss. Can it treat depression, too?

Questions loom on AstraZeneca cancer drug as safety concerns ebb

hotspot

leisure time

leisure time

Wikipedia